9 Menopause Myths That Were Created or Amplified by Commercial Interests on Both Sides of the HRT Debate
What struck me most when researching this was how often the same woman has been frightened twice — first told hormones would give her cancer, then told that if she just took the right supplements she would barely notice menopause at all. Both stories were exaggerated, and both exaggerations made someone money. Women deserve better than being a battleground.
Learn more about Rose →Myth: The Women's Health Initiative proved HRT causes breast cancer in all women
The 2002 WHI study generated global headlines declaring HRT dangerous, and pharmaceutical companies that had aggressively over-marketed hormones as anti-ageing drugs did not push back hard on the narrative — the legal liability risk made silence commercially rational. What the study actually showed was a modestly elevated breast cancer risk in one group of women (older, combined HRT, synthetic progestogen) that has since been substantially recontextualised by re-analyses showing the risk varies considerably by age of initiation, type of progestogen, and route of administration. The blanket 'HRT causes breast cancer' claim that dominated two decades of medical practice was never what the full evidence supported.
Myth: 'Bioidentical' hormones from wellness compounding pharmacies are safer than regulated HRT
The term 'bioidentical' was largely popularised not by researchers but by a wellness and compounding pharmacy industry that correctly identified a market of women frightened away from conventional HRT after 2002. Compounded hormone preparations are not subject to the same manufacturing standards, batch consistency testing, or safety surveillance as regulated products, meaning the safety advantage claimed for them has no meaningful evidence base — and in some cases introduces real risks of dosing inconsistency. Regulated estradiol and micronised progesterone are chemically identical to those sold under the bioidentical banner, making the distinction primarily a marketing one rather than a pharmacological one.
Myth: Menopause supplements can meaningfully replace hormones for severe symptoms
The supplement industry expanded rapidly into the menopause space after 2002, and the commercial incentive to position products as a 'natural alternative' to now-feared HRT was enormous. Ingredients like black cohosh, red clover isoflavones, and maca have been studied, and while some show modest effects on mild vasomotor symptoms, no supplement has demonstrated efficacy comparable to estrogen therapy for moderate-to-severe hot flushes, genitourinary symptoms, or bone protection. Women with debilitating symptoms who are told supplements are a comparable option are being given commercially convenient information, not clinically accurate information.
Myth: Pharmaceutical companies originally promoted HRT purely for symptom relief
From the 1960s through to the 1990s, hormone therapy was marketed with claims that extended well beyond symptom management — Premarin advertising positioned estrogen as the key to staying youthful, feminine, and mentally sharp in ways that were not grounded in robust evidence at the time. This commercial over-reach was a genuine problem that inflated expectations, contributed to widespread over-prescribing to women who had mild or no symptoms, and ultimately made the WHI's findings land harder than they might have in a more measured prescribing culture. The current evidence supports HRT for specific indications — it was the industry-driven 'hormone for every woman forever' framing that was always wrong.
Myth: Phytoestrogens from soy are a proven, evidence-based alternative to estrogen therapy
Soy isoflavones have been heavily marketed for menopause by food and supplement companies, often with references to lower rates of hot flushes in Japanese women — a population-level observation that does not translate straightforwardly into clinical evidence for supplementation. Randomised controlled trials on phytoestrogen supplements show inconsistent results, with effect sizes typically small and studies often industry-funded or methodologically limited. Whole soy foods as part of a balanced diet carry no meaningful risk and may offer modest benefit, but the leap from that to a bottled supplement being a hormone replacement is a commercial stretch, not a scientific one.
Myth: All progestogens in HRT carry the same risk profile
After the WHI findings, a broad cultural and clinical conflation occurred between all forms of progestogen — the synthetic progestins used in the WHI and oral contraceptives were treated as interchangeable with micronised progesterone, which has a meaningfully different pharmacological profile and a more reassuring observational safety record, particularly regarding breast and cardiovascular risk. Generic 'HRT is dangerous' messaging benefited the wellness industry, while regulated pharmaceutical companies producing micronised progesterone had insufficient commercial incentive to fund the large-scale trials that would have clarified the distinction sooner. The nuance matters clinically and women were largely denied access to it for years.
Myth: Menopause is a hormone deficiency disease that should always be treated medically
Early pharmaceutical marketing framed menopause explicitly as a deficiency state — most infamously in Robert Wilson's 1966 book 'Feminine Forever,' which was later revealed to have been funded by Wyeth, a major estrogen manufacturer. This framing was commercially useful because deficiency states imply universal treatment need, expanding the potential market from symptomatic women to essentially all postmenopausal women. The evidence-based position is more measured: menopause is a natural physiological transition, HRT is an effective and appropriate option for women with significant symptoms or specific risk factors, and there is no universal clinical mandate to treat it in women who are coping well.
Myth: 'Natural' menopause supplements are inherently safe because they are plant-based
The wellness industry's use of 'natural' as a proxy for 'safe' is a commercial framing strategy rather than a pharmacological fact, and it has been particularly effective in the menopause supplement market where women are actively trying to avoid perceived pharmaceutical risk. Several commonly sold menopause supplements interact with medications — black cohosh has rare but documented associations with liver toxicity, and red clover isoflavones may interact with anticoagulants and hormone-sensitive conditions. 'Natural' tells a woman nothing useful about safety, dosing consistency, or contraindications, and the absence of regulatory scrutiny that makes supplements appealing to some manufacturers is precisely what removes a layer of consumer protection.
Myth: The current wave of pro-HRT advocacy is purely evidence-driven and has no commercial dimension
The recent and genuinely welcome correction in clinical guidance — acknowledging that HRT had been over-restricted in the post-WHI years and restoring access for appropriate candidates — is largely supported by good evidence, but it has also coincided with significant commercial investment in menopause as a category by pharmaceutical companies, femtech platforms, and private menopause clinics with subscription models. Some advocacy content circulating online and in media, while broadly accurate in its pro-HRT messaging, is produced by or financially connected to commercial interests that benefit from increased prescribing, and women are rarely given the tools to identify those connections. Welcoming better evidence does not require accepting uncritically every claim made in its name.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.